Medindia LOGIN REGISTER
Medindia
Advertisement

ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide

Wednesday, July 30, 2008 General News
Advertisement
FREDERICK, Md., July 29 ImQuest BioSciences announcedtoday the successful acquisition of funding from the National Institute ofAllergy and Infectious Disease (NIAID/NIH) to support the development ofpyrimidinedione inhibitors as topical microbicides to prevent the sexualtransmission of HIV. The two year Small Business Innovative Research (SBIR)grant provides funding for the continued development of the dual-actingpyrimidinedione molecules which effectively inhibit two critical steps in theHIV replication pathway important for a microbicide. The research to beperformed will enable ImQuest scientist's to comparatively evaluate their mostpotent lead preventative agents and define the most potent microbicidecandidate for advanced preclinical and clinical development.
Advertisement

ImQuest's Executive Vice President and Chief Scientific Officer, Dr.Robert W. Buckheit, Jr. is the Principal Investigator of the project and leadsImQuest's efforts to develop microbicide and therapeutic products fortreatment and prevention of HIV infection. "Women now account for over 50% ofthe cases of individuals living with AIDS and the successful development of amicrobicide is essential for providing them with an effective means to protectthemselves from infection," explained Dr. Buckheit. "In the absence of aneffective vaccine, topical microbicides represent the best means to preventnew HIV infections throughout the world."
Advertisement

As a component of the grant, ImQuest scientists will work in collaborationwith Dr. Patrick Kiser of The University of Utah to develop an optimalformulated gel product which can be used by women to prevent the sexualtransmission of HIV. ImQuest plans to file an IND to initiate human clinicalmicrobicide trials with their lead microbicide candidate in 2009.

ImQuest Life Sciences, a privately held U.S. company located in Frederick,Maryland specializes in early stage drug development of novel compounds forthe treatment of infectious disease and cancer. ImQuest BioSciences, alsolocated in Frederick, Maryland, is a leading provider of anti-infectivetherapeutic and microbicide development services to the biotechnology andpharmaceutical industry.For further information regarding this press release please contact: Robert W. Buckheit, Jr., Ph.D. Executive Vice President and Chief Scientific Officer ImQuest Life Sciences, Inc. 301-696-0274 [email protected]

SOURCE ImQuest BioSciences
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close